> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Delays Review of Pfizer COVID-19 Vaccine for Children Under 5 to Await Third-Dose Data
- URL: https://www.theamericanquorum.com/taq-historical-2022-02-12-healthcare/
- Published: 2022-02-13T04:59:00.000Z
- Updated: 2022-02-13T04:59:00.000Z
- Description: FDA postponed its February 15 review of Pfizer’s under-5 COVID-19 vaccine, choosing to wait for third-dose trial data before considering authorization.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-31 09:11

The Food and Drug Administration has postponed a planned February 15 advisory committee meeting on Pfizer and BioNTech’s COVID-19 vaccine for children under 5, saying it will wait for additional data on a third dose before deciding whether the vaccine should be authorized for the youngest Americans.

The reversal came less than two weeks after the agency asked the companies to begin a rolling submission for a two-dose regimen in children 6 months through 4 years old. Pfizer and BioNTech said Friday that accumulating evidence suggested regulators would have a more complete basis for a decision after the trial produces results from a third 3-microgram dose. The companies’ [update](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-rolling-submission?ref=theamericanquorum.com) said the rolling application remains open while the new data are collected.

The FDA’s [postponement notice](https://www.fda.gov/advisory-committees/advisory-committee-calendar/postponed-vaccines-and-related-biological-products-advisory-committee-february-15-2022-meeting?ref=theamericanquorum.com) means families who had anticipated a possible authorization this month will wait longer. Children under 5 remain the only major U.S. age group without access to a COVID-19 vaccine.

## The two-dose data produced an uneven result

Pfizer and BioNTech selected a 3-microgram dose for infants and preschool-age children, one-tenth of the adult and adolescent dose. Their study tested two doses given three weeks apart, with immune responses compared against those seen in vaccinated young adults.

In a December [trial update](https://www.pfizer.com/news/announcements/pfizer-and-biontech-provide-update-ongoing-studies-covid-19-vaccine?ref=theamericanquorum.com), the companies said the two-dose series met the study’s immunogenicity target in children 6 months through 2 years but did not meet that standard in children ages 2 through 4\. Rather than increasing the individual dose, the protocol was amended to test a third 3-microgram shot at least two months after the second.

That finding created a difficult regulatory question. A two-dose series might offer some protection sooner, particularly during a period of intense Omicron circulation, but the manufacturer’s own trial suggested that the ultimate regimen may need three doses to generate a more consistent immune response across the entire under-5 population.

## The FDA initially chose an accelerated review

On February 1, Pfizer and BioNTech said they had started a [rolling submission](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency?ref=theamericanquorum.com) at the FDA’s request. The approach allowed the agency to review manufacturing, safety and immune-response data as they became available rather than waiting for every part of the application to be complete.

The FDA simultaneously scheduled an advisory panel meeting and said it intended to consider the available evidence promptly. Its original [announcement](https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-advisory-committee-meeting-to-discuss-request-for-authorization-of-pfizer-biontech-covid-19-vaccine-for-children-6-months-through-4-years-of-age-301473265.html?ref=theamericanquorum.com) described a public review in which outside experts would examine the request and vote on whether the known and potential benefits of vaccination outweighed the risks.

Friday’s postponement indicates that the agency now believes the third-dose data could materially change that benefit-risk judgment. Waiting may reduce the chance of authorizing a schedule that is soon replaced, but it also extends the period during which parents of infants and toddlers have no vaccination option.

## Omicron has changed the standard for protection

The development program began before Omicron became dominant. The variant’s ability to cause breakthrough infections has altered expectations about what constitutes adequate protection, particularly against mild and moderate disease.

A January [JAMA analysis](https://jamanetwork.com/journals/jama/fullarticle/2788485?ref=theamericanquorum.com) of symptomatic infections during Omicron circulation found substantially greater protection after a third mRNA vaccine dose than after two doses among adults. Pediatric dosing cannot be inferred directly from adult booster studies, but the broader evidence reinforces the biological plausibility that an additional antigen exposure can improve protection against an immune-evasive variant.

At the same time, regulators must avoid assuming that more doses are automatically better. Young children have different immune systems, body size, baseline disease risk and reactogenicity profiles. The trial is designed to determine whether a third very small dose provides a sufficiently stronger immune response without compromising safety.

## The youngest children remain outside the vaccination program

The FDA authorized a 10-microgram Pfizer dose for children ages 5 through 11 in October, and that program has been operating for several months. Children under 5, however, generally receive vaccines through pediatric practices and have different developmental and dosing considerations.

The delay is therefore more than a scheduling change. It means pediatricians and parents will continue relying on layered prevention—vaccination of household members, testing, ventilation, masking where practical and staying home when ill—while waiting for a product specifically authorized for infants and preschoolers.

Pfizer and BioNTech have not abandoned the application. They expect third-dose information in the coming weeks and plan to complete the submission once those data are available. If the immune response is stronger across both age cohorts, the FDA could return to the advisory committee with a clearer proposed regimen.

The episode demonstrates the tension inherent in emergency regulation during a rapidly changing pandemic. Speed matters when millions of people lack a preventive option, but the value of speed diminishes if the evidence suggests the proposed schedule may be incomplete. By postponing the meeting, the FDA has chosen to wait for a more mature dataset before deciding how the youngest Americans should be vaccinated.